Life Edit Therapeutics
Xiuying Li is a seasoned scientist with extensive experience in the fields of non-viral gene delivery and nanoformulation. Currently serving as a Senior Scientist at Life Edit Therapeutics since April 2023, Xiuying focuses on novel lipid nanoparticle (LNP) discovery and process development. Prior to this, Xiuying worked at IMMORNA, where responsibilities included the design and development of various nanoformulations for mRNA delivery. Experience also includes a role as Formulation Scientist II at Nexus Pharmaceuticals, where Xiuying developed complex injectable drug products and supported ANDA submissions. At The University of Texas at Dallas, Xiuying held positions as a Research Scientist and Research Associate, where significant contributions included the invention of a smart photo-mechanic sensitive vesicle and the development of advanced drug release techniques. Educational qualifications include a PhD in Pharmaceutical Sciences from the Shanghai Institute of Materia Medica and a visiting PhD student position at Novo Nordisk A/S and Copenhagen University.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.